Next Article in Journal
Blocking TRPA1 in Respiratory Disorders: Does It Hold a Promise?
Next Article in Special Issue
Applications of High-Throughput Sequencing for In Vitro Selection and Characterization of Aptamers
Previous Article in Journal
The Development of a Parenteral Pharmaceutical Formulation of a New Class of Compounds of Nitrosourea
Previous Article in Special Issue
Aptamers: A New Technological Platform in Cancer Immunotherapy
Article Menu

Export Article

Open AccessFeature PaperReview
Pharmaceuticals 2016, 9(4), 69; doi:10.3390/ph9040069

Aptamer-Mediated Targeted Delivery of Therapeutics: An Update

Istituto per I’Endocrinologia e I’Oncologia Sperimentale del CNR “G. Salvatore”, Via S. Pansini 5, 80131 Naples, Italy
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editors: Alfredo Berzal-Herranz and Cristina Romero-López
Received: 5 October 2016 / Revised: 27 October 2016 / Accepted: 28 October 2016 / Published: 3 November 2016
(This article belongs to the Special Issue Aptamers: Biomedical Interest and Applications)
View Full-Text   |   Download PDF [2133 KB, uploaded 3 November 2016]   |  

Abstract

The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer–nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies. View Full-Text
Keywords: aptamers; drug delivery; targeted therapy aptamers; drug delivery; targeted therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Catuogno, S.; Esposito, C.L.; de Franciscis, V. Aptamer-Mediated Targeted Delivery of Therapeutics: An Update. Pharmaceuticals 2016, 9, 69.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top